FDA approves a next-generation Covid vaccine from Moderna, with restrictions
The Food and Drug Administration recently granted approval for Moderna’s new Covid-19 vaccine, mNexspike, adding another weapon in the fight against the ongoing pandemic. This new vaccine, while not immediately replacing the existing Spikevax, will provide an additional option for those at high risk of severe illness from Covid-19. Both vaccines will be available on the market for the time being, offering more choices for individuals seeking protection.
The FDA’s approval comes with specific restrictions on the use of mNexspike. Unlike Spikevax, which is licensed for individuals aged 12 and older, the new vaccine is approved for use only in people aged 65 and older, as well as those aged 12 to 64 with underlying medical conditions that increase their risk of severe illness from Covid-19. These conditions include diabetes, COPD, and obesity, among others.
The approval of mNexspike marks a significant milestone for Moderna, especially considering the skepticism surrounding mRNA-based vaccines. Despite concerns raised by some political figures, billions of doses of mRNA vaccines have been administered globally with minimal reported side effects. The new vaccine utilizes a refined target to produce antibodies against the SARS-CoV-2 virus, allowing for a smaller dosage compared to Spikevax.
In a Phase 3 trial comparing mNexspike to Spikevax, the new vaccine demonstrated higher antibody levels, particularly among older adults. The FDA has requested post-marketing studies from Moderna to further assess the safety and effectiveness of mNexspike, including an observational study on the outcomes of pregnant individuals and their babies when the vaccine is administered during pregnancy.
However, challenges may arise in conducting these studies, as recent decisions by health officials have raised questions about vaccine recommendations for certain populations. Despite the CDC’s previous recommendation for pregnant individuals to receive Covid vaccines, recent changes on their website have created confusion regarding this guidance. Additionally, the FDA has requested a new trial to determine the benefits of Covid vaccination in adults aged 50 to 64.
Overall, the approval of Moderna’s new Covid vaccine offers hope in the ongoing battle against the pandemic. With continued research and monitoring, these vaccines play a crucial role in protecting individuals at high risk of severe illness from Covid-19.
